Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMOVI: Eteplirsen in Duchenne Muscular Dystrophy
NCT02255552Phase 3Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Nov 2014
- Primary completion
- Jun 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 3 trial of eteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Started Nov 2014; status: completed.
02
Drugs
eteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02255552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02255552.